A versatile luminescent probe for sensing and monitoring amyloid proteins

A modified lysine residue containing an environment-sensitive moiety was prepared through a straightforward synthesis, and its fluorescent properties were examined. The new fluorescent sensor, DMN-BocK, can monitor amyloid aggregation processes associated with neurodegenerative diseases such as Alzh...

Descripción completa

Detalles Bibliográficos
Autores: Vázquez Bigas, Guillem, Espargaró Colomé, Alba, Caballero Hernández, Ana Belén, Di Pede Mattatelli, Ania, Busquets i Viñas, Ma. Antonia, Nawrot, Daria, Sabaté Lagunas, Raimon, Nicolás Galindo, Ernesto, Juárez Jiménez, Jordi, Gámez Enamorado, Patrick
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/223397
Acceso en línea:https://hdl.handle.net/2445/223397
Access Level:acceso abierto
Palabra clave:Proteïnes
Malalties neurodegeneratives
Amiloides
Espectroscòpia de fluorescència
Proteins
Neurodegenerative Diseases
Amyloid
Fluorescence spectroscopy
Descripción
Sumario:A modified lysine residue containing an environment-sensitive moiety was prepared through a straightforward synthesis, and its fluorescent properties were examined. The new fluorescent sensor, DMN-BocK, can monitor amyloid aggregation processes associated with neurodegenerative diseases such as Alzheimer’s or Parkinson’s. DMN-BocK offers advantages over classical amyloid-specific dyes like Thioflavins or Congo Red because it is (1) available to detect a broader range of amyloid structures; (2) useful both in vitro and in cellulo; (3) capable of differentiating amyloid structures, providing information on the binding site microenvironment; and (4) a synthon than can be incorporated into protein sequences to gain further structural information. Our findings suggest that DMN-based amino-acid probes have a strong potential to become a sensor of choice for in vitro and in cellulo studies of amyloid aggregation in drug discovery assays.